Power3 Medical Products, Inc. (OTCBB:PWRM) released that company management believes Power3 is making great progress in its focus on the development, sales, and marketing of its proprietary innovate diagnostic tests for breast cancer, pancreatic cancer, ovarian cancer, colon cancer, and certain neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, to name a few.

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) specializes in the research and development of novel drugs and diagnostic products for the aging population. Nymox Pharmaceutical’s lead drug candidate is NX-1207, a proprietary treatment for enlarged prostate or benign prostatic hyperplasia (BPH). NX-1207 is currently in Phase 3 trials in the United States.

“We are very excited to be finally ridding ourselves of litigation that has plagued us for several years now,” stated Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc.

Everyone has been touched by America’s oil and natural gas industry. Farmers use fertilizer that comes from natural gas. Truckers use diesel fuel to transport goods to the markets. Proper Power & Energy, Inc. (OTCBB:PPWE) has announced that Proper Power & Energy has been approached by two independent financing groups and has submitted a $10 million private placement memorandum to each of them.